Clinical Trial Update: Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older [Phase 3]

View source ↗

Summary

This Phase 3 trial update reports immunogenicity and safety results for GlaxoSmithKline's recombinant zoster vaccine (Shingrix) when co-administered with GSK's …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• GSK2321138A (seasonal influenza vaccine)
• Shingrix (recombinant zoster vaccine, adjuvanted)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Herpes Zoster | Phase 3 | Status: COMPLETED | Results posted: 2016-02-10